Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 151

1.

A Phase III open-label trial to evaluate efficacy and safety of CPI-613 plus modified FOLFIRINOX (mFFX) versus FOLFIRINOX (FFX) in patients with metastatic adenocarcinoma of the pancreas.

Philip PA, Buyse ME, Alistar AT, Lima CM, Luther S, Pardee TS, Cutsem EV.

Future Oncol. 2019 Sep 12. doi: 10.2217/fon-2019-0209. [Epub ahead of print]

PMID:
31512497
2.

DNA-Methylation-Caused Downregulation of miR-30 Contributes to the High Expression of XPO1 and the Aggressive Growth of Tumors in Pancreatic Ductal Adenocarcinoma.

Azmi AS, Li Y, Aboukameel A, Muqbil I, Philip PA, Mohammad RM.

Cancers (Basel). 2019 Aug 2;11(8). pii: E1101. doi: 10.3390/cancers11081101.

3.

Optimizing the management of locally advanced pancreatic cancer with a focus on induction chemotherapy: Expert opinion based on a review of current evidence.

Seufferlein T, Hammel P, Delpero JR, Macarulla T, Pfeiffer P, Prager GW, Reni M, Falconi M, Philip PA, Van Cutsem E.

Cancer Treat Rev. 2019 Jul;77:1-10. doi: 10.1016/j.ctrv.2019.05.007. Epub 2019 May 29. Review.

PMID:
31163334
4.

Adjuvant treatment of surgically resectable pancreatic ductal adenocarcinoma.

Tesfaye AA, Philip PA.

Clin Adv Hematol Oncol. 2019 Jan;17(1):54-63. Review.

PMID:
30843899
5.

Phase IB/II Randomized Study of FOLFIRINOX Plus Pegylated Recombinant Human Hyaluronidase Versus FOLFIRINOX Alone in Patients With Metastatic Pancreatic Adenocarcinoma: SWOG S1313.

Ramanathan RK, McDonough SL, Philip PA, Hingorani SR, Lacy J, Kortmansky JS, Thumar J, Chiorean EG, Shields AF, Behl D, Mehan PT, Gaur R, Seery T, Guthrie KA, Hochster HS.

J Clin Oncol. 2019 May 1;37(13):1062-1069. doi: 10.1200/JCO.18.01295. Epub 2019 Feb 28.

PMID:
30817250
6.

Ras and exosome signaling.

Sexton RE, Mpilla G, Kim S, Philip PA, Azmi AS.

Semin Cancer Biol. 2019 Feb;54:131-137. doi: 10.1016/j.semcancer.2019.02.004. Epub 2019 Feb 12. Review.

PMID:
30769101
7.

Molecular Profiling of Appendiceal Adenocarcinoma and Comparison with Right-sided and Left-sided Colorectal Cancer.

Tokunaga R, Xiu J, Johnston C, Goldberg RM, Philip PA, Seeber A, Naseem M, Lo JH, Arai H, Battaglin F, Puccini A, Berger MD, Soni S, Zhang W, Hwang JJ, Shields AF, Marshall JL, Baba H, Korn WM, Lenz HJ.

Clin Cancer Res. 2019 May 15;25(10):3096-3103. doi: 10.1158/1078-0432.CCR-18-3388. Epub 2019 Jan 28.

PMID:
30692096
8.

Outcomes in Patients With Metastatic Pancreatic Adenocarcinoma With the Introduction of New Chemotherapeutic Drugs: 10-Year Experience of a Single NCI-designated Comprehensive Cancer Center.

Zhang KJ, Dyson G, Gatz JL, Silverman ME, Tesfaye AA, Shields AF, Philip PA.

Am J Clin Oncol. 2019 Mar;42(3):243-246. doi: 10.1097/COC.0000000000000507.

PMID:
30601178
9.

Pharmacotherapeutic strategies for treating pancreatic cancer: advances and challenges.

Diab M, Azmi A, Mohammad R, Philip PA.

Expert Opin Pharmacother. 2019 Apr;20(5):535-546. doi: 10.1080/14656566.2018.1561869. Epub 2018 Dec 28. Review.

PMID:
30592647
10.

miRNA and Gene Expression in Pancreatic Ductal Adenocarcinoma.

Tesfaye AA, Azmi AS, Philip PA.

Am J Pathol. 2019 Jan;189(1):58-70. doi: 10.1016/j.ajpath.2018.10.005. Review.

PMID:
30558723
11.

Impact of Patient Age on Molecular Alterations of Left-Sided Colorectal Tumors.

Puccini A, Lenz HJ, Marshall JL, Arguello D, Raghavan D, Korn WM, Weinberg BA, Poorman K, Heeke AL, Philip PA, Shields AF, Goldberg RM, Salem ME.

Oncologist. 2019 Mar;24(3):319-326. doi: 10.1634/theoncologist.2018-0117. Epub 2018 Jul 17.

PMID:
30018131
12.

Comparative Molecular Analyses of Esophageal Squamous Cell Carcinoma, Esophageal Adenocarcinoma, and Gastric Adenocarcinoma.

Salem ME, Puccini A, Xiu J, Raghavan D, Lenz HJ, Korn WM, Shields AF, Philip PA, Marshall JL, Goldberg RM.

Oncologist. 2018 Nov;23(11):1319-1327. doi: 10.1634/theoncologist.2018-0143. Epub 2018 Jun 4.

PMID:
29866946
13.

Metastatic Pancreatic Cancer: ASCO Clinical Practice Guideline Update.

Sohal DPS, Kennedy EB, Khorana A, Copur MS, Crane CH, Garrido-Laguna I, Krishnamurthi S, Moravek C, O'Reilly EM, Philip PA, Ramanathan RK, Ruggiero JT, Shah MA, Urba S, Uronis HE, Lau MW, Laheru D.

J Clin Oncol. 2018 Aug 20;36(24):2545-2556. doi: 10.1200/JCO.2018.78.9636. Epub 2018 May 23.

PMID:
29791286
14.

Landscape of Tumor Mutation Load, Mismatch Repair Deficiency, and PD-L1 Expression in a Large Patient Cohort of Gastrointestinal Cancers.

Salem ME, Puccini A, Grothey A, Raghavan D, Goldberg RM, Xiu J, Korn WM, Weinberg BA, Hwang JJ, Shields AF, Marshall JL, Philip PA, Lenz HJ.

Mol Cancer Res. 2018 May;16(5):805-812. doi: 10.1158/1541-7786.MCR-17-0735. Epub 2018 Mar 9.

15.

Consensus statement on mandatory measurements in pancreatic cancer trials (COMM-PACT) for systemic treatment of unresectable disease.

Ter Veer E, van Rijssen LB, Besselink MG, Mali RMA, Berlin JD, Boeck S, Bonnetain F, Chau I, Conroy T, Van Cutsem E, Deplanque G, Friess H, Glimelius B, Goldstein D, Herrmann R, Labianca R, Van Laethem JL, Macarulla T, van der Meer JHM, Neoptolemos JP, Okusaka T, O'Reilly EM, Pelzer U, Philip PA, van der Poel MJ, Reni M, Scheithauer W, Siveke JT, Verslype C, Busch OR, Wilmink JW, van Oijen MGH, van Laarhoven HWM.

Lancet Oncol. 2018 Mar;19(3):e151-e160. doi: 10.1016/S1470-2045(18)30098-6.

PMID:
29508762
16.

Retraction notice to "Increased Ras GTPase activity is regulated by miRNAs that can be attenuated by CDF treatment in pancreatic cancer cells" [Cancer Lett. 319(2) (2012) 173-181].

Ali S, Ahmad A, Aboukameel A, Bao B, Padhye S, Philip PA, Sarkar FH.

Cancer Lett. 2018 Feb 1;414:313. doi: 10.1016/j.canlet.2017.11.030. No abstract available.

17.

The evolution into personalized therapies in pancreatic ductal adenocarcinoma: challenges and opportunities.

Tesfaye AA, Kamgar M, Azmi A, Philip PA.

Expert Rev Anticancer Ther. 2018 Feb;18(2):131-148. doi: 10.1080/14737140.2018.1417844. Epub 2017 Dec 19. Review.

18.

Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma.

Javle M, Lowery M, Shroff RT, Weiss KH, Springfeld C, Borad MJ, Ramanathan RK, Goyal L, Sadeghi S, Macarulla T, El-Khoueiry A, Kelley RK, Borbath I, Choo SP, Oh DY, Philip PA, Chen LT, Reungwetwattana T, Van Cutsem E, Yeh KH, Ciombor K, Finn RS, Patel A, Sen S, Porter D, Isaacs R, Zhu AX, Abou-Alfa GK, Bekaii-Saab T.

J Clin Oncol. 2018 Jan 20;36(3):276-282. doi: 10.1200/JCO.2017.75.5009. Epub 2017 Nov 28.

19.

Comparative molecular analyses of left-sided colon, right-sided colon, and rectal cancers.

Salem ME, Weinberg BA, Xiu J, El-Deiry WS, Hwang JJ, Gatalica Z, Philip PA, Shields AF, Lenz HJ, Marshall JL.

Oncotarget. 2017 Sep 21;8(49):86356-86368. doi: 10.18632/oncotarget.21169. eCollection 2017 Oct 17.

20.

Exportin 1 (XPO1) inhibition leads to restoration of tumor suppressor miR-145 and consequent suppression of pancreatic cancer cell proliferation and migration.

Azmi AS, Li Y, Muqbil I, Aboukameel A, Senapedis W, Baloglu E, Landesman Y, Shacham S, Kauffman MG, Philip PA, Mohammad RM.

Oncotarget. 2017 Jul 17;8(47):82144-82155. doi: 10.18632/oncotarget.19285. eCollection 2017 Oct 10.

Supplemental Content

Loading ...
Support Center